Interleukin 24 gene therapy - MultiVir

Drug Profile

Interleukin 24 gene therapy - MultiVir

Alternative Names: Ad-IL 24 - MultiVir; Ad-IL24; Adenoviral interleukin 24 - MultiVir; IL24 gene therapy - MultiVir

Latest Information Update: 31 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MultiVir
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Malignant melanoma
  • No development reported Head and neck cancer

Most Recent Events

  • 18 May 2017 Results from a preclinical trial in Malignant melanoma released by MultiVir
  • 15 Apr 2016 Phase-I clinical trials in Malignant melanoma (Combination therapy) in USA (unspecified route)
  • 14 Feb 2014 Phase-I clinical trials in Head and neck cancer (combination therapy, recurrent) in USA (unspecified route) before February 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top